Page 9 - Emonstrate News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

MB-106 continues to demonstrate favorable safety and efficacy profile Overall response rate of 83% in cohort with durable responses observed; one patient remains in complete remission at 22 months . | June 12, 2023

Mazyar shadmanManuel litchmanTony plohorosBrian tillJaclyn jaffeFred hutchDrug administrationEuropean hematology associationFred hutchinson cancer center hutchCompany contactGlobenewswire incLifesci advisorsCompany nasdaqExchange commissionSecurities exchangeFortress biotech inc

Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress

- Both trials met the primary and key secondary endpoints at the pre-specified interim analysis - - Data continue to demonstrate transformative and durable benefit - - Safety profile consistent. | June 9, 2023

United statesCity ofUnited kingdomSan franciscoFranco locatelliExagamglogene autotemcelCarmen bozicAmerican society of hematology annual congressEuropean hematology associationDepartment of pediatric hematologyVertex pharmaceuticalsEuropean commissionViacyte incEuropean medicines agencySapienza university of romeCompanies to work

Stellantis Adapts Top Executive Team to Lead Company Through Increasingly Challenging External Environment

Stellantis Adapts Top Executive Team to Lead Company Through Increasingly Challenging External Environment
webwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from webwire.com Daily Mail and Mail on Sunday newspapers.

Noord hollandUnited statesTimothy kuniskisCarlos tavaresSilvia vernettiMark stewartGiorgio fossatiMike kovalHarald westerOlivier franTimothy kuniskiOlivier bourgesNed curicGlobal corporate officeTop executive teamPublic affairs officer

Atara Biotherapeutics Presents Updated Tab-cel® Clinical Effectiveness Data at ASCO 2023

Real-World Results Demonstrate Objective Response Rate of 67% in 24 EBV+ PTLD Patients 91% Overall Survival at One Year for Patients Responding to Tab-cel Compared to 34% for. | June 5, 2023

Mccormick placeUnited statesFrance generalPierre fabreRalf trappeSylvain choquetAtara biotherapeutics incAmerican society of clinical oncologyAccess programMccormick place convention center chicagoExpanded access programClinical oncologyAnnual meetingComplete responsePartial responseChief medical officer

Gartner Identifies Three Pillars of Human Leadership CFOs Need in an Era of Finance AI

The rapid progress of AI tools in the finance function in recent times has made it more important than ever for CFOs and finance leaders to demonstrate three core pillars of human leadership:. | June 5, 2023

Dennis gannonNational harborGartner incGartner financeExecutive conferenceNc stock exchangePress releaseUman it us3666511072